Randolph W. Hubbell - Jul 18, 2023 Form 4 Insider Report for ALPHA HEALTHCARE ACQUISITION CORP III (CTCX)

Role
CEO & President, Director
Signature
/s/ Randolph W. Hubbell
Stock symbol
CTCX
Transactions as of
Jul 18, 2023
Transactions value $
$0
Form type
4
Date filed
7/18/2023, 08:33 PM
Previous filing
Jul 18, 2023
Next filing
Aug 30, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTCX Stock Option (right to buy) Award +217K 217K Jul 14, 2023 Common Stock 217K $1.79 Direct F1, F4
transaction CTCX Stock Option (right to buy) Award +37.6K 37.6K Jul 14, 2023 Common Stock 37.6K $2.27 Direct F2, F4
transaction CTCX Stock Option (right to buy) Award +480K 480K Jul 14, 2023 Common Stock 480K $2.11 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options are fully vested and exercisable.
F2 Options to purchase 37,642 shares of common stock of Legacy Carmell (as defined below) granted on July 19, 2019, which vest as follows: 25% vested on July 19, 2020, July 19, 2021 and July 19, 2022. The remaining 25% will vest and become exercisable on July 19, 2023.
F3 Options to purchase 480,110 shares of common stock of Legacy Carmell granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2022 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.
F4 On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation.